Business Context and Reporting Period
This Form 8-K Current Report was filed by Shuttle Pharmaceuticals Holdings, Inc. on May 11, 2023, covering events occurring on May 8 and May 10, 2023. The Company is a Delaware corporation and an emerging growth company focused on cancer therapies.
Key Financial Metrics
This filing does not contain standard financial statements, revenue, profit, or cash flow data. The only specific financial figures disclosed relate to a debt amendment:
- Existing Debt: $4.3 million convertible note held by Alto Opportunity Master Fund.
- Existing Warrants: Warrant to purchase 1,018,079 shares of common stock.
- Collateral Release: $1.5 million in cash collateral to be released to the Company ($1.0 million immediately; $0.5 million upon filing of Schedule 14C).
- Potential Future Debt: Authorization to issue up to an additional $10 million in convertible notes subject to shareholder approval.
Material Changes
The filing reports two material events:
- Amendment to Securities Purchase Agreement: The Company amended its agreement with Alto Opportunity Master Fund. Key changes include removing a provision regarding warrant share adjustments and stipulating that the Company would obtain majority shareholder approval to issue up to $10 million in additional convertible notes and warrants. These new instruments would be sold to Alto on substantially the same terms as the existing note and warrant.
- Patent Award: The Company received notice that its U.S. Patent Application No. 16/475,999 was approved. U.S. Patent No. 11,654,157, titled "Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With Radiation," is scheduled for issuance on May 23, 2023.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or management commentary on future performance. However, it notes the following contingencies and actions:
- Shareholder Approval: The Company obtained majority stockholder consent in advance of the Amendment Agreement for the potential sale of the Subsequent Notes and Warrants.
- Regulatory Filing: The Company is required to file a Schedule 14C within 30 calendar days of the Amendment Agreement regarding the potential issuance of shares related to the Subsequent Notes and Warrants.
- Dilution Risk: The potential issuance of the Subsequent Notes and Warrants would cause the issuance of in excess of 19.9% of the Company's issued and outstanding stock.
Investor Verification Checklist
- Verify the terms of the Amendment Agreement attached as Exhibit 10.1.
- Confirm the filing of the Schedule 14C within the required 30-day window.
- Monitor the release of the $1.5 million cash collateral from Alto.
- Review the full text of U.S. Patent No. 11,654,157 once issued on May 23, 2023.
- Assess the potential dilution impact of the additional $10 million in convertible notes.